Publication date: Oct 31, 2024
Immunocompromised people are facing ongoing inequality in health outcomes because of COVID-19. Let’s remain ambitious and improve availability and access to COVID-19 prevention therapies that protect patients and aid management. This article brings together opinions from four experts based in the United Kingdom who specialise in immunology, solid organ transplantation, respiratory medicine and critical care, oncology and haematology. In this article, they communicate the impact of SARS-CoV-2 infection on vulnerable patients with underlying conditions and the need for immediate policies to protect vulnerable people from COVID-19.
| Concepts | Keywords |
|---|---|
| Covid | health policy |
| Immunocompromised | immunocompromised |
| Inequality | long-COVID |
| Organ | vaccination |
| Vulnerable people |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Tropicamide |
| disease | MESH | COVID-19 |
| pathway | REACTOME | SARS-CoV-2 Infection |
Original Article
(Visited 3 times, 1 visits today)